Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure
暂无分享,去创建一个
Ronan Boulmé | Dimitri Gonzalez | Daniel Olive | D. Olive | P. Halfon | G. Pénaranda | H. Khiri | C. Sayada | R. Boulmé | Philippe Halfon | Sofiane Mohamed | Guillaume Penaranda | Claire Camus | Hacène Khiri | Chalom Sayada | Patrick Philibert | P. Philibert | Sofiane Mohamed | Claire Camus | D. Gonzalez | C. Camus
[1] D. Olive,et al. Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV‐1 infected patients , 2014, Journal of medical virology.
[2] Rolf Kaiser,et al. Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response , 2013, PloS one.
[3] K. Metzner,et al. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. , 2013, Journal of Infectious Diseases.
[4] R. Shafer,et al. Update of the drug resistance mutations in HIV-1: March 2013. , 2013, Topics in antiviral medicine.
[5] S. Sirivichayakul,et al. Comparison of predicted susceptibility between genotype and virtual phenotype HIV drug resistance interpretation systems among treatment-naive HIV-infected patients in Asia: TASER-M cohort analysis , 2012, BMC Research Notes.
[6] P. Massip,et al. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[7] R. Kagan,et al. A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients , 2012, PloS one.
[8] D. O’Connor,et al. Low-Cost Ultra-Wide Genotyping Using Roche/454 Pyrosequencing for Surveillance of HIV Drug Resistance , 2012, PloS one.
[9] M. Danzer,et al. Human immunodeficiency virus type 1 drug resistance testing: Evaluation of a new ultra-deep sequencing-based protocol and comparison with the TRUGENE HIV-1 Genotyping Kit. , 2011, Journal of virological methods.
[10] Niko Beerenwinkel,et al. Ultra-deep sequencing for the analysis of viral populations. , 2011, Current opinion in virology.
[11] J. Aerssens,et al. Minor variant detection in amplicons using 454 massive parallel pyrosequencing: experiences and considerations for successful applications. , 2011, BioTechniques.
[12] Jun Yong Choi,et al. Detection of Minority Resistance during Early HIV-1 Infection: Natural Variation and Spurious Detection rather than Transmission and Evolution of Multiple Viral Variants , 2011, Journal of Virology.
[13] Jeffrey N. Martin,et al. Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy , 2010, Journal of acquired immune deficiency syndromes.
[14] S. Hammer,et al. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. , 2010, The Journal of infectious diseases.
[15] R. Paredes,et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. , 2010, The Journal of infectious diseases.
[16] Kevin Dieckhaus,et al. Low-Abundance HIV Drug-Resistant Viral Variants in Treatment-Experienced Persons Correlate with Historical Antiretroviral Use , 2009, PloS one.
[17] Gregory S Turenchalk,et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. , 2009, The Journal of infectious diseases.
[18] A. Lazzarin,et al. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies , 2009, AIDS.
[19] K. Metzner,et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] P. Mee,et al. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa , 2008, AIDS.
[21] Tommy F. Liu,et al. Minority Human Immunodeficiency Virus Type 1 Variants in Antiretroviral-Naive Persons with Reverse Transcriptase Codon 215 Revertant Mutations , 2008, Journal of Virology.
[22] Michael Monsour,et al. Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.
[23] Mark Myatt,et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment , 2008, Antiviral therapy.
[24] B. Schmidt,et al. Differences of nine drug resistance interpretation systems in predicting short-term therapy outcomes of treatment-experienced HIV-1 infected patients: a retrospective observational cohort study. , 2007, European journal of medical research.
[25] J. Eshleman,et al. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. , 2006, The Journal of molecular diagnostics : JMD.
[26] A. Vandamme,et al. Algorithms for the interpretation of HIV-1 genotypic drug resistance information. , 2006, Antiviral research.
[27] Lynn Morris,et al. Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent , 2006, Antimicrobial Agents and Chemotherapy.
[28] L. Pérez-Alvárez,et al. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[29] John W. Mellors,et al. Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis , 2005, Journal of Clinical Microbiology.
[30] F. Heinz,et al. Comparison of virtual phenotype and HIV‐SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains , 2002, HIV medicine.
[31] S. Staszewski,et al. Comparison of Nine Resistance Interpretation Systems for HIV-1 Genotyping , 2002, Antiviral therapy.
[32] B. Larder,et al. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing , 1993, Nature.